Shares of ProQR Therapeutics rose 10% in premarket trading after it said the Food and Drug Administration had granted an orphan-drug designation to QR-1123. The experimental therapy is being tested as a treatment for vision loss caused by autosomal dominant retinitis pigmentosa (adrp), a rare eye disease. “Our goal is to develop and actively advance a pipeline of programs that can treat inherited retinal diseases like adRP in a targeted manner,” ProQR CEO Daniel de Boer said in a news release. ProQR stock is down 51% year-to-date, while the S&P 500 has gone up 24%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Latest posts by Market Watch (see all)
- The Margin: How to grow your Twitter following from 400 to 75,000 in one weekend: Get into a feud with Mike Huckabee - December 9, 2019
- As Fed chairman, Paul Volcker made everyone mad - December 9, 2019
- Market Snapshot: Stocks lower, still within striking distance of records as trade deadline looms - December 9, 2019